Evaluation of ATF-2 expression and its clinical significance in DLBCL
Objective: Detection of Activating Transcription Factor-2 (ATF-2) expression in Diffuse Large B-cell Lymphoma (DLBCL) and its relationship with clinicopathological significance. Method: Pathological diagnosis and clinical data were collected in DLBCL. Immunohistochemical (IHC) was applied for ATF...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Editorial Board of Journal of Hainan Medical University
2017-05-01
|
| Series: | Journal of Hainan Medical University |
| Subjects: | |
| Online Access: | http://www.hnykdxxb.com/PDF/201709/28.pdf |
| Summary: | Objective: Detection of Activating Transcription Factor-2 (ATF-2) expression in
Diffuse Large B-cell Lymphoma (DLBCL) and its relationship with clinicopathological
significance. Method: Pathological diagnosis and clinical data were collected in DLBCL.
Immunohistochemical (IHC) was applied for ATF-2 expression in DLBCL. Result: Positive
rate of ATF2 expression in DLBCL was 81% (64/79). We found ATF2 expression was not
related to gender, age, clinical staging, immunological phenotype, and EBV infection, Ki-
67, CyclinD1 and Bcl-2. The positive rate of both ATF-2, Bcl-6 was 62.0% (49/79), ATF-2
was associated with Bcl-6; the higher expression of ATF-2 is correlated with the poor survival
time in DLBCL. Conclusion: High expression of ATF-2 expression is associated with poor
prognosis in DLBDL, suggesting that ATF-2 may be an independent prognostic factor for
diffuse large B cell lymphoma. |
|---|---|
| ISSN: | 1007-1237 1007-1237 |